Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.




 Recombinant self-replicating polycistronic rna molecules patent thumbnailRecombinant self-replicating polycistronic rna molecules
This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies.
Glaxosmithkline Biologicals, Sa


 Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers patent thumbnailNovel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Contructs for enhancing immune responses patent thumbnailContructs for enhancing immune responses
Chimeric protein constructs including a herpesvirus glycoprotein d (gd) and a heterologous polypeptide that interact with herpes virus entry mediator (hvem) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.. .
The Wistar Institute Of Anatomy And Biology


 Methods and compositions for enhancing immune responses patent thumbnailMethods and compositions for enhancing immune responses
Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an mva vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response.
The United Of America, As Represented By The Secretary, Department Of Health And Human Services


 Treatment for cutaneous t cell lymphoma patent thumbnailTreatment for cutaneous t cell lymphoma
The present invention provides method for treating a patient with cutaneous t cell lymphoma (ctcl). Generally, the methods include administering to the patient an irm compound in an amount effective to ameliorate at least one symptom or clinical sign of ctcl.
3m Innovative Properties Company


 Compositions and methods for treating clostridium difficile infection patent thumbnailCompositions and methods for treating clostridium difficile infection
Clostridium difficile is the most common hospital acquired pathogen in the united states, and infection is in many cases fatal. Toxins a and b are its major virulence factors, but increasingly a third toxin may be present, known as c.
University Of Virginia Patent Foundation


 Immunogenic wt-1 peptides and methods of use thereof patent thumbnailImmunogenic wt-1 peptides and methods of use thereof
This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt-1-expressing cancer, comprising peptides derived from the wt-1 protein.. .
Memorial Sloan Kettering Cancer Center


 Lipidated immune response modifier compound compositions, formulations, and methods patent thumbnailLipidated immune response modifier compound compositions, formulations, and methods
The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company


 Poxviral vaccines patent thumbnailPoxviral vaccines
The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed..
Glaxosmithkline Biologicals, Sa


 Size tunable microbial mimetics for immunotherapy of cancer patent thumbnailSize tunable microbial mimetics for immunotherapy of cancer
The mm exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The mm constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo..

Target peptides for immunotherapy and diagnostics

A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/mhc complex..
The University Of Birmingham

Koc1-derived peptide and vaccine including same

The present invention provides koc1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Cross-protective pathogen protection, methods and compositions thereof

The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies.

Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s

Human papilloma virus constructs

Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (hpv).
The Regents Of The University Of Colorado, A Body Corporate

Non-lipidated variants of neisseria meningitidis orf2086 antigens

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated orf2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic.
Wyeth Llc

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Nlrc5 as a biomarker for cancer patients and a target for cancer therapy

The invention pertains to biomarkers for identifying a cancer that is likely or not likely to evade the immune system of a subject, thus, is likely or not likely to show better prognosis (prognostic biomarker) and/or better responses to cancer therapies (predictive biomarker). The invention provides a method of identifying a subject as having a cancer that is likely to evade the immune system of the subject based on one or more of the following biomarkers in the cancer cells of the subject: a) reduced amount of nlrc5 mrna or protein; b) reduced activity of nlrc5 protein; c) a mutation that reduces the activity of nlrc5 protein; d) increased methylation of nlrc5 or a portion thereof; and e) reduced copy number of nlrc5.
The Texas A&m University System

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s

Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal t cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (myco) bacterially and/or virally infected cells or tumor cells.
Academisch Ziekenhuis Leiden

Methods and compositions for enhancing immune response

Methods and compositions for enhancing the immune response to an irm compound by depositing within a localized tissue region an irm depot preparation that provides an extended residence time of active irm within the localized tissue region.. .
3m Innovative Properties Company

Compositions and methods for self-adjuvanting vaccines against microbes and tumors

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide must be present in a complex of three or more units in order to stimulate an immune response.
The Regents Of The University Of California

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Mhc-i restricted epitopes containing non-natural amino acid residues

The invention provides for the synthesis of more effective generators of a t-cell immune response by providing peptide derivatives that are mhc class i-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the c-terminus..
Purdue Pharma L.p.

Detection of an immune response

Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a th2a subset of cd4+ t cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of cd4+ t cells in a biological sample of said subject; (b) detecting a frequency of a th2a subset of the cd4+ t cells in the biological sample; and (c) comparing the frequency of the th2a subset with the frequency of the cd4+ t cells..

Methods and compositions pertaining to human cerebral cavernous malformations

The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of ccms in patients, and that blocking those responses treats the ccm. Described herein is a method for treating ccms in a patient in need thereof comprising administering a therapeutically effective amount of a b-cell immunomodulation therapy to the patient..

Modified virus-like particles of cmv

The present invention relates to virus-like particles of plant virus cucumber mosaic virus (cmv), and in particular to modified vlps of cmv comprising th cell epitopes, in particular universal th cell epitopes. Furthermore, these modified vlps serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified vlps.

Branched oligonucleotides

Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.. .

Modulation of nkt cell activity with antigen-loaded cd1d molecules

The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble cd1d complexes, in particular non-specific soluble cd1d complexes. Soluble cd1d complexes comprise a soluble cd1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the cd1d antigen binding groove, and in certain embodiments, an immunogen.

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

The present description relates to t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as igf2bp3-001 have the amino acid sequence of kiqeiltqv (seq id no:1).

Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy

Cell-based therapies for cartilage repair and regeneration selectively using chondrocytes carrying a cd24 surface marker are disclosed. In particular, chondrocytes carrying the cd24 surface marker have a high regenerative potential and low responsiveness to inflammatory cues.

Compositions comprising ch848 envelopes and uses thereof

In certain aspects the invention provides immonogenic compositions comprising ch848 hiv-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.. .

Platform for the identification of tumor-associated cancer/testes antigens

Methods of identifying cancer/testes antigens (ctas) useful as cancer treatment targets are disclosed and claimed herein. The methods include identifying human sperm proteins to which patients diagnosed with solid or hematological malignancies have established a humoral immune response..
Kiromic Biopharma, Inc.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.
Novartis Ag

Glycoengineered binding protein compositions

Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..
Abbvie Inc.

Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria.
The University Of Chicago

Immunotherapy against melanoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods of modulating immune system responses

Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a tifa activator such heptose-1,7-5 bisphosphate or an analogue or derivative thereof.
The Governing Council Of The University Of Toronto

Vaccination of immunocompromised subjects

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided..
Seqirus Uk Limited

Compositions and methods for increasing immunogenicity of glycoprotein vaccines

The present invention relates to the microbial immunogens engineered to bear α-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, old world monkey or bird cells that have been engineered to express an α1,3galactosyltransferase (α 1,3gt) gene to produce virions bearing hemagglutinin molecules containing α-gal epitopes, to increase the immunogenicity of the influenza virus.
University Of Massachusetts

Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus ankara-based (mva-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) mva and fpv vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a marburg virus (marv) or ebola virus glycoprotein.
Bavarian Nordic A/s

Attenuated mannheimia haemolytica strains

The present invention provides attenuated m haemolitica strains that elicit an immune response in animal against m haemolitica, compositions comprising said strains, methods of vaccination against m haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease..
Biotechnology Research And Development Corporation

Compositions and methods for immunizing against c. difficile

This disclosure relates to methods for eliciting an immune response against c. Difficile toxin a and toxin b in an adult human subject.
Sanofi Pasteur, Inc.

Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells

Disclosed are compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of nr2f6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use.
Regen Biopharma, Inc.

Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells

Described herein are compositions and techniques related to generation and therapeutic application of stem cell-derived exosomes. The inventors have discovered cardiosphere-derived cells (cdcs) and their secreted exosomes mediate such inflammatory processes, by, for example, shifting macrophages away from a proinflammatory m1 phenotype toward m2 healing phenotype.
Cedars-sinai Medical Center

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Prefusion rsv f proteins and their use

Disclosed are immunogens including a recombinant rsv f protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens.

New immunostimulatory compounds

The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan entamoeba histolytica. The compounds have been found to be useful for enhancing and/or inducing an immune response in a subject in need thereof.

Prolyl hydroxylase inhibitors

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (hif-1α), as well as hypoxia inducible factor-2 (hif-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds.

Single wall nanotube constructs and uses thereof

The present invention provides soluble single wall nanotube (swnt) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble swnt via a dna or other oligomer platform attached to the swnt.

Frictional trans-epithelial tissue disruption collection apparatus and inducing an immune response

The invention relates to trans-epithelial frictionally abrasive tissue sampling devices for performing biopsies and methods of inducing an immune response against a pathogen, wherein epithelial cells containing the pathogen are disrupted with the frictionally abrasive tissue sampling device to introduce the pathogen into the bloodstream of a patient.. .

Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Synergistic compositions of immunostimulating reconstituted influenza virosomes with immunopotentiators and vaccines containing them

The present invention is directed to a preparation of an adjuvant system to achieve required level of humoral and cellular immune response against antigen of interest. The current invention provides an adjuvant system comprising an immunostimulating reconstituted influenza virosomes (irivs) and immunopotentiators.

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..

Compositions and methods for modulating an immune response

The disclosure relates to, among other things, agents that modulate the homophilic interaction between two cracc polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal.
Board Of Trustee Of Michigan State University

Pichinde virus reverse genetics systems and methods of use

Provided herein are genetically engineered pichinde viruses that include three ambisense genomic segments. The first genomic segment includes a coding region encoding a z protein and a coding region encoding a l rdrp protein.
Regents Of The University Of Minnesota

Modulation of stimulatory and non-stimulatory myeloid cells

Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein such as an antibody or antigen binding fragment thereof.. .
The Regents Of The University Of California

Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin

Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus ankara (mva) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased t-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. A human subject, and related methods and uses..
Bavarian Nordic A/s

Vlps containing ligands and methods related thereto

This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a tlr5 agonist on the exterior without an antigen..
Children's Healthcare Of Atlanta, Inc.

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.. .
Sotio A.s.

Priming of an immune response

The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.. .
University Of Copenhagen

Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against aml and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure

A monocomponent vaccine effective to moderate the clinical consequences of chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a c-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of trypanosoma cruzi fused to the c-terminal region.

Heartworm vaccine, methods and uses thereof

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence.
Merial Inc.

Compositions and methods for treating and preventing inflammation

The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting nrp1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting sema3a-mediated cell signaling..
Rsem, Limited Partnership

Cancer vaccine compositions and methods of use thereof

The present application describes compositions that include an epitope of a peptide that elicits an immune response in a subject following administration. The compositions described herein include nucleic acids.
University Of Washington

Immune system modulation for prophylaxis and treatment of diseases and disorders

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms.
Marpe Holdings, Llc

Combination therapy for inducing immune response to disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Compositions and methods for enhanced innate immunity

The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (tlr3) and toll like receptor 9 (tlr9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces.
Colorado State University Research Foundation

Low, immune enhancing, dose mtor inhibitors and uses thereof

The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mtor inhibition, e.g., with low, immune enhancing, doses of an mtor inhibitor, such as rad001.. .
Novartis Institutes For Biomedical Research, Inc.

H3.3 ctl peptides and uses thereof

Peptides that generate an immune response to glioma-related h3.3 proteins and methods of their use are provided.. .
Regents Of The University Of California

Method of treatment using liposomally formulated reduced glutathione to cooperate with il-10 to modulate inflammatory response triggered in hiv+ and tb immune-compromised diabetic patients

In the setting of chronic infection with a pathogen, the immune system must adapt to the ongoing presence of inflammatory responses driven by the pathogen in order to control the replication of the infecting agent at an acceptable level while limiting immune-mediated damage (immunopathology) (1). A complex interaction is required to accomplish this using a balance of immune related cytokines to stimulate and control the immune response.
Western University Of Health Sciences

Immunomodulation using spores and pollen grains

The present invention includes compositions, methods of making and using the compositions for modulating the immune response in a subject by providing a vaccine composition having a pollen or spore disposed in a pharmaceutical carrier for delivery to a subject, wherein the pollen or spore comprises multiple pores that connect an outer surface of the pollen/spore to an inner cavity and one or more antigens disposed on the outer surface, in the inner cavity, in the multiple pores, or a combination thereof, wherein the one or more antigens modulate an immune responses in the subject.. .
Texas Tech University System

Antibodies and molecules derived therefrom that bind to steap-1 proteins

Antibodies and molecules derived therefrom that bind to novel steap-1 protein, and variants thereof, are described wherein steap-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i. Consequently, steap-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
Agensys, Inc.

Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (taa) and at least one binding site for an antigen expressed on an effector t cell, nk cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a taa-expressing tumor.
Ibc Pharmaceuticals, Inc.

Herpes simplex virus vaccine

Herpes simplex virus (hsv) antigens that elicit an hsv-specific immune response and can be used to treat or prevent hsv infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against hsv, treat or prevent hsv disease, induce a t cell response against hsv, and induce an antibody response against hsv also are provided..
Genvec, Inc.

Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection

Dengue fever (df) and dengue hemorrhagic fever (dhr) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive t cell responses.
Emergex Vaccines Holdings Limited

Compositions and methods for the prevention and treatment of cancer

Conventional cancer immunotherapy falls short at efficiently expanding t cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with mhc class i and/or class ii molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic t cells to levels not achieved in current immunotherapeutic techniques.
Uti Limited Partnership

Treatment of cancer using tlr9 agonist with checkpoint inhibitors

The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more tlr9 agonists and one or more checkpoint inhibitors. Preferably, the one or more tlr9 agonists are administered to the patient via intratumoral (i.t.) administration..
Idera Pharmaceuticals, Inc.

Mass-spectral selection, and de-selection, of cancer patients for treatment with immune response generating therapies

A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated ras-based cancer, alone or in combination with another anti-cancer therapy. The method uses mass spectrometry of a blood-derived patient sample and a computer configured as a classifier using a training set of class-labeled spectra from other cancer patients that either benefited or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy.
Globeimmune Inc.

Ompa in vaccine compositions and as diagnostic targets

Anaplasma marginale surface protein ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Compositions and methods for modulating immune responses

The present invention provides a newly identified b7 receptor, zb7r1 that functions as lymphocyte inhibitory receptor, which is a pd-1-like molecule and is expressed on t cells. The present invention also provides the discovery of zb7r1's ability to bind to cd155.
Zymogenetics, Inc.

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides.
Oncomed Pharmaceuticals, Inc.

Fviii peptides for immune tolerance induction and immunodiagnostics

The present invention is related to peptides that can be used to reduce the immune response against fviii or to induce tolerance to human fviii in patients with, e.g., hemophilia a. Furthermore, the peptides can be used for immunodiagnostic purposes to detect fviii-specific cd4+ t cells to monitor patients with hemophilia a during replacement therapy and during immune tolerance induction therapy..
Baxalta Gmbh

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Disclosed are t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as mag-003 have the amino acid sequence of kvlehvvrv (seq id no:1).
Immatics Biotechnologies Gmbh

Compositions including beta-glucans and use

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a tlr agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen.
Biothera, Inc.

Mutant porcine epizootic diarrhea virus for use in a vaccine

The invention relates to a mutant porcine epizootic diarrhea virus (pedvdn), to methods of producing said pedvdn, and to compositions comprising the pedvdn. The invention further relates to methods of stimulating an immune response in a pig comprising administering the pedvdn, to vaccines comprising the pedvdn, and to methods for preventing or ameliorating porcine epizootic diarrhoea in a pig..
Universiteit Utrecht Holding B.v.

Peptides and combination of peptides for use in immunotherapy against cancers

The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods of identifying antigens for vaccines

The methods, processes, and systems described herein include identifying an epitope of a peptide that may elicit an immune response in a subject. Often the methods, systems and processes may include designing and producing a composition comprising an epitope of a peptide identified using the methods or processes described herein..
University Of Washington Through Its Center For Commercialization

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response to determine if said response is depressed. A method for restoring her2-specific cd4+ th1 immune response in a her2-positive breast cancer patient in need thereof, comprising: administering to said patient a therapeutically effective amount of a dendritic cell (“dc”) vaccine comprising autologous dcs pulsed with her2-derived mhc class ii binding peptides (“dc vaccination”) to elevate said patient's anti-her2 cd4+ th1 response, and measuring said anti-her2 th1 response of said patient pre- and post-dc vaccination to determine the amount of increase in said response..
The Trustees Of The University Of Pennsylvania

Antigen-binding fusion proteins with modified hsp70 domains

The invention relates to fusion proteins comprising an antigen binding domain fused with a modified heat shock 70 protein. The invention further relates to methods of using the fusion proteins to induce an immune response to antigens and to treat diseases associated with antigens..
Aperisys, Inc.

Gitr antibodies, methods, and uses

Provided herein are antibodies that specifically bind to gitr. Also described are related polynucleotides capable of encoding the provided gitr-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments.
Janssen Biotech, Inc.

T cell-redirected antigen-binding molecule for cells having immunosuppression function

It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a t cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking t cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.. .
Osaka University

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.
Axon Neuroscience Se

Uterine cancer treatments

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections

The present invention is drawn to conjugates and vaccine compositions comprising a pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more klebsiella surface polysaccharide antigens, such as klebsiella pneumoniae o5 polysaccharide from serovars o1, o2a, o2a,c, o3, o4, o5, o7, o8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions..

Skin penetrating peptides (spps) and methods of use therefor

The present disclosure provides peptides and peptide compositions, optionally in the from of a vaccine, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (sc) and/or the cellular membranes of viable cells. Also provided are methods of employing the peptides and peptide compositions to deliver active agents; treat diseases or disorders; and inducing immune responses..
Ctx Technology Inc.

Antagonism of the vip signaling pathway

Inhibition of the vip signaling pathway with vip antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a vip antagonist to a subject in combination with a cell.
Emory University

Versikine for inducing and potentiating an immune response

Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a t-cell mediated immune response. The methods comprise administering to the subject, or to explanted cells of the subject, a pharmaceutical composition comprising an effective amount of versikine or a variant of versikine that induces the t-cell mediated immune response.
Wisconsin Alumni Research Foundation

Novel mucosal vaccination approach for herpes simplex virus type-2

The invention provides methods and kits for immunizing animals (e.g. Mammals) against viral antigens, including herpes-simplex virus type 2.
Biomedical Research Models, Inc.

Compositions and methods to treat aids

Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins.
University Of Massachusetts

Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb)

We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (gvhd) or epidermolysis bullosa (eb). The homeostasis may comprise immune homeostasis such as maintenance of an immune response.
Agency For Science, Technology And Research

Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

The disclosure provides among others a combination of a vaccine and a cd94/nkg2a and/or a cd94/nkg2b binding antibody for use in the treatment of a subject in need thereof, wherein said vaccine comprises an immunogen for eliciting an immune response against an antigen or a nucleic acid molecule encoding said immunogen.. .
Academisch Ziekenhuis Leiden H.o.d.n. Lumc

Anti-pd-l1 antibodies and uses thereof

The present application relates to anti-pd-l1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.. .
Merck Patent Gmbh

Anti-pd-l1 antibodies and uses thereof

The present application relates to anti-pd-l1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.. .
Merck Patent Gmbh

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compound and method

The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalisation method in which a cytokine, preferably gm-csf, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods.
Pci Biotech As

Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.
Curevac Ag

Organic vaccination an alternative method to traditional preventative vaccination

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive t and b lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject.

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Three-component-multistage malaria vaccine

The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Frauhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Protein-chaperoned t-cell vaccines

Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone.
Massachusetts Institute Of Technology

Autologous implantation of chimeric murine-human tumors, generated in pdx mice, for ativation of an anti-tumor immune response in the donor patient

Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in pdx mice, back to the original donor patients.

Immunomodulating compositions and methods of use thereof

This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for o-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Progenitor cells, preparation thereof and uses thereof

The present application provides progenitor cells and a preparing method thereof. The preparing method comprises obtaining a tissue sample containing myometrium from uterus, treating the tissue sample with collagenase, and culturing the treated tissue sample to obtain the progenitor cells, wherein the progenitor cell is multipotent and immunomodulatory.
National Health Research Institutes

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof

The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide-protein (os-pr) conjugates. The process of synthetic os-pr conjugation is a rapid process providing oligosaccharide-protein conjugates which are highly immunogenic and elicit specific and homogenous immune responses.
Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.

Novel immunostimulatory method

This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a tlr2 moiety in solution, wherein the tlr2 moiety comprises a tlr2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the tlr2 moiety.. .
Innavac Pty Ltd

Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response.
The Regents Of The University Of Michigan

Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

A vaccine comprising an immunologically effective amount of recombinant modified vaccinia ankara (rmva) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified h5 (mh5) promoter operably linked to a dna sequence encoding a heterologous foreign protein antigen, wherein the expression of said dna sequence is under the control of the mh5 promoter; b) generating rmva virus by transfecting one or more plasmid vectors obtained from step a) into wild type mva virus; c) identifying rmva virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rmva virus strain identified by step d); and f) purifying the rmva viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (cmv) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of immediate-early gene-1 or immediate-early gene-2 (iefusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine..
City Of Hope

T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

The present invention concerns methods and compositions for treatment of hiv infection using a t20 expression vector, such as that shown in seq id no:1 or seq id no:3. The t20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to hiv, localized transfection in vivo in a gene therapy approach to provide longer term delivery of t20, or in vitro production of t20 peptide.
Immunomedics, Inc.

Method of quickly producing antibodies against avian influenza and maintain antibody titer of duck

The present invention provides a method for enabling ducklings to quickly produce anti-avian influenza antibodies and maintain antibody titer, including: step 1) the first immunization is performed on ducklings at the age of 5 to 15 days: each duckling is inoculated with an avian influenza inactivated antigen in an abdomen, and simultaneously intramuscularly or subcutaneously immunized with an avian influenza inactivated oil-emulsion vaccine. In the method, through the double effects of intraperitoneal inoculation with the inactivated antigen and intramuscular or subcutaneous injection with the inactivated oil-emulsion vaccine on the ducklings, the ducklings can quickly produce an immune response so as to quickly produce the anti-avian influenza antibodies; and the immune dead time of the ducklings immunized with the avian influenza inactivated vaccine can be effectively reduced by more than 7 days..
South China Agricultural University

Attenuated mannheimia haemolytica vaccines and methods of making and use

The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m.
Merial Inc.

Staphylococcus aureus materials and methods

The disclosure generally relates to the field of prevention and treatment of staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the staphylococcus aureus epitopes and methods for treating staphylococcus aureus infection with the antibody products..
The Regents Of The University Of Michigan

Immunogenic polypeptide cocktail for the treatment of medullary thyroid carcinoma

Disclosed are immunogenic compositions that include one or more polypeptides that, when administered to a subject with adjuvant, elicit an immune response against medullary thyroid cancer. Disclosed are methods of eliciting an immune response and/or treating cancer, such as medullary thyroid carcinoma or other thyroid carcinomas..

Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof

Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.. .
City Of Hope

Compositions and methods for treating b cell mediated autoimmune disorders

Provided herein are methods, kits, compositions and uses related to the treatment of a b cell mediated autoimmune disorder with a t cell vaccine comprising a therapeutically effective amount of t cells autologous to the patient and that react to an autoantigen or specific epitope(s) thereof associated with the b cell mediated autoimmune disorder, wherein the treatment is provided to a patient in need thereof having suppressed b cell immune responses.. .
Opexa Therapeutics, Inc.

Innate immune modulating molecule complex for the activation of the innate immune system of aquatic animals and methods therefor

A method for application of an innate immune modulating molecule complex to activate the innate immune system of aquatic animals includes selecting a recombinant dna with characteristics configured for activating aquatic animal macrophages, such as by inducing an innate immune response in the animal. The method for application of an innate immune modulating molecule complex also includes selecting an adjuvant with characteristics favorable for activating aquatic animal macrophages and causing the release of cytokines.
Perkins Biosystems, Llc

Antiviral treatment with low immunogenicity

Compositions and methods are disclosed for reducing toxicity and immunogenicity of nucleases, especially when in use for cutting viral nucleic acids in host cells. Different nucleases that cut the same target are delivered at different times to avoid an immune response that interferes with a therapeutic effect of the nucleases..
Agenovir Corporation

Antigen specific mrna cellular cancer vaccines

Disclosed are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mrna encoding said immunogenic epitopes. In one embodiment of the invention, said modified mrna encodes peptides derived from the protein survivin.
Regen Biopharma, Inc

Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory disorders

A method of using a composition including dihydroquercetin, as well as optionally α-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described..
Bionoox Suisse Sa

Method and kit for detection of mycobacteria

A method of determining whether an individual is infected with mycobacteria. The method comprising the steps of (a) providing a system which comprises at least two different mycolic-acid derived antigens; (b) introducing a sample obtained from the individual into the system and into contact with each of the at least two different mycolic-acid derived antigens; and (c) detecting the presence or absence of the binding of a biomarker in the sample with each antigen in the system.
Diagnostig Ltd

Actrii antagonists for use in increasing immune activity

Disclosed herein are actrii antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an actrii antagonists and a pd1-pdl1 antagonist..
Acceleron Pharma Inc.

Human alpha-folate receptor chimeric antigen receptor

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified t cell having α-folate receptor (frα) binding domain and cd27 costimulatory domain to treat ovarian cancer.
The Trustees Of The University Of Pennsylvania

Compositions and methods for modulating t-cell mediated immune response

The present disclosure relates to compositions and methods for modulating t-cell mediated immune response in a subject in need thereof. The method includes administering to the subject an effective amount of a cd112r protein, a fusion polypeptide, a complex including cd112r and a second protein, or an anti-cd112r antibody of the present disclosure..
The Regents Of The University Of Colorado

Compositions and methods related to neurological disorders

The present technology relates to compositions comprising inulin particles for use in the enhancement of immune responses to neuronal self-antigens for treating or preventing neurodegenerative diseases, in a subject. Also provided are pharmaceutically acceptable compositions comprising: particles of inulin; a substance comprising one or more pathogen-associated molecular patterns (pamps); and a neuronal self-antigen fused to carrier, and methods and uses of the composition for inducing or modulating an immune response in a subject, such as modulating an immune response to a neuronal self-antigen as a vaccine.
Vaxine Pty Ltd

Antiviral vaccines with improved cellular immunogenicity

The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects..
Los Alamos National Security, Llc

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof.
Regeneron Pharmaceuticals, Inc.

Vaccines against streptococcus pneumoniae serotype 8

The present invention relates to synthetic saccharides of general formula (i) that are related to streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (i) are useful as marker in immunological assays for detection of antibodies against streptococcus pneumoniae bacteria..
Max-planck-gesellschaft Zur FÖrderung Der Wissenschaften E.v.

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of cd40l/cd40 receptor axis with complex of glycolipid/cd1d receptor in nkt cells and in dendritic cells

A combination of components to promote an innate and adaptive immune response comprising of a taa/ecdcd40l vaccine and a complex between the cd1d receptor and an alpha galactosyl ceramide like glycolipid (agclgl), to activate nkt cells and activate the cd40 receptor on the dcs and increase the level of the adaptive immune response induced by the taa/ecdcd40l vaccine to the taa. The result and advantage of using both the taa/ecdcd40l vaccine and the α-galactosylceramide-cd1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the cd40l/cd40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e.
Microvax,llc

Combination immunotherapy approach for treatment of cancer

Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response.
Stemimmune, Incorporated

Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein tryptophan2,3-di-oxygenase (tdo) or peptide fragments here of that are capable of eliciting anti-cancer immune responses.
Herlev Hospital

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

A genetically modified mesenchymal stem cell (msc) and medical use thereof in the treatment of tumors, the msc including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.
Apceth Gmbh & Co. Kg

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Markers of immune response

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory t cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.. .
Stallergenes

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Virus like particle comprising pd-1 antigen or pd-1 ligand antigen

The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from pd-1 or a ligand of pd-1, and a composition or kit comprising thereof, its use in immune response etc.. .
Vlp Therapeutics, Llc

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising interleukin-2 (il-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of interleukin-2 receptor alpha (il-2rα) or a functional variant or fragment thereof, and wherein the fusion protein has il-2 activity.
University Of Miami

Recombinant hiv-1 envelope proteins and their use

Hiv-1 env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the hiv-1 env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to hiv-1 in a subject.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Vaccines having an antigen and interleukin-21 as an adjuvant

Disclosed herein is a vaccine comprising an antigen and il-21. Also disclosed herein are methods for increasing an immune response in a subject.
The Trustees Of The University Of Pennsylvania

Vaccine in the form of a recombinant sero type 9 avian adenovirus vector

The vector of this vaccine is stable for industrial scale production. Likewise, even when administering this vaccine in combination with a vaccine against marek's disease, both vaccines produce an adequate immune response which is not affected by interference between each other.

Novel antigen for use in malaria

The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in dna or other recombinant protein expression systems delivered as a vaccine formulation..
Camris International, Inc.

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Treatment of inflammatory and dysimmune response

A drug and, more particularly, to a drug for treating inflammatory and dysimmune response. The present invention also relates to a drug for treating graft-versus-host disease.
Chu De Dijon

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Method for in vivo expansion of t regulatory cells

Compositions specific for tnf-receptor superfamily member 25 (tnfrsf25, dr3) modulate the immune response by regulating t regulatory cells.. .
University Of Miami

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Methods of modulating an immune response

The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to a filovirus (e.g., marburg virus (marv)), including antibodies that cross-react with at least two filoviruses. Such antibodies are useful for the prevention and treatment of filovirus infection.

Adenocarcinoma antigenic determinants and methods

Adenocarcinoma antigenic determinants, methods for their production and use, and broadly-specific human monoclonal antibodies reactive to the epitopes. These epitopes, which can be physically recapitulated, are conserved across a range of adenocarcinomas and are capable of eliciting an immune response in humans..
Vaccinogen, Inc.

Vaccine adjuvant compositions

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave t cells to differentiate into ifn-γ-producing t cells, and for preventing and treating infections. The combinatorial composition comprises tlr and clr agonists.
Children's Medical Center Corporation

Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)

Disclosed are therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2). More particularly, the invention relates to a method for inducing an immune response in a subject by introducing and expressing an hsv gd2-encoding dna vaccine..
Admedus Vaccines Pty Ltd

Recombinant bacterium and methods of antigen and nucleic acid delivery

The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.. .
The Arizona Board Of Regents For And On Behalf Of Arizona State University

Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens.
Glaxosmithkline Biologicals Sa

Cancer therapy using a vaccine in combination with a cell-based immunotherapeutic agent

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel.
Xeme Biopharma Inc.

Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a delivery system

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule..
Xeme Biopharma Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..
Quorum Innovations, Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Malaria antigen screening method

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (apcs) in vitro or to an animal in vivo.
United States Of America As Represented By The Secretary Of The Navy

Expression system for modulating an immune response

The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.. .
Admedus Vaccines Pty Ltd.

Compositions and methods related to antibodies to staphylococcal protein a

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria.
The University Of Chicago

Innate immune system modification for anticancer therapy

The present invention relates to the discovery of a role of the nuclear receptor retinoid-related orphan receptor gamma (rorgamma) in tumor suppression. The introduction and expression of rorgamma result in genes activation within innate immune cells that trigger recognition and suppression of tumor cells.
Yale University

Messenger rna nanoparticles and preparation method therefor

Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mrna nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid dna itself but in the form of mrna, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid dna via rolling circle transcription (rct), thereby providing a simple and economical process for gene delivery.
University Of Seoul Industry Cooperation Foundation

Vaccine pharmaceutical composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as serratia, lelercia, rahnella, acidicaldus, acidiphilium, acidisphaera, acidocella, acidomonas, asaia, belnapia, craurococcus, gluconacetobacter, gluconobacter, kozakia, leahibacter, muricoccus, neoasaia, oleomonas, paracraurococcus, rhodopila, roseococcus, rubritepida, saccharibacter, stella, swaminathania, teichococcus, zavarzinia, pseudomonas, achromobacter, bacillus, methanoculleus, methanosarcina, clostridium, micrococcus, flavobacterium, pantoea, acetobacter, zymomonas, xanthomonas, and enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500..
Nitto Denko Corporation

Vaccine for treatment and prevention of herpes simplex virus infection

The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses.
Agenus Inc.

Compositions and methods for transient immune response modulation during vaccination

In certain aspects the invention provides a selection of hiv-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize.
Duke University

Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof

The present invention relates to the preparation and use in primates of whole organismvaccines in which the mep pathway is disrupted such that synthesis of hmbpp by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active mep pathway are used in vaccine methods, the γδ t cell response dominates, potentially clearing the vaccine strain via γδ t cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of cd4+ and cd8+ αβ t cell responses, specific for listerial-encoded antigens.
Providence Health & Services-oregon D/b/a Providence Portland Medical Center

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Inoculation by applying nanosecond pulsed electric fields to a biopsy and reintroducing the treated biopsy to the subject

A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nspef). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells.
Pulse Biosciences, Inc.

Methods and therapeutic combinations for treating tumors

Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an immune response modifier compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds..
Board Of Regents, The University Of Texas System

Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome

The present invention relates to the field of clostridium difficile infections. Methods of diagnosing, treating and preventing clostridium difficile-associated disease and recurrent cdad are disclosed herein..
Assistance Publique - Hopitaux De Paris

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Carbon nanotube compositions and methods of use thereof

Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens.
Yale University

Monovalent anti-cd3 adjuvants

This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna

The nuclear reprogramming of somatic cells with mrna encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of pkr, of toll-like receptors, e.g.
The Board Of Trustees Of The Leland Stanford Junior University

Antagonistic peptides

The present invention relates to a compositions and methods for treating and/or preventing neurologic disorders such as alzheimer's disease and disorders associated with an increase of the th2 immune response such as allergic inflammation.. .
Deakin University

Vaccine delivery method

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological ph, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions..
University Of Georgia Research Foundation, Inc.

Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine.
Curevac Ag

Methods and compositions for inhibiting akt3

Compounds and compositions for selectively inhibiting akt3 are provided. Methods of using the compounds are also provided.
Augusta University Research Institute, Inc.

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection.
Seqirus Uk Limited

Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response

Methods are disclosed for producing defective ribosomal products (drips) in blebs (dribbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. Dribbles can be used to load antigen presenting cells (apcs), thereby allowing the apcs to present the drips and antigenic fragments thereof.
Providence Health & Services - Oregon

Computationally optimized broadly reactive antigens for influenza

The development of a computationally optimized influenza ha protein that elicits broadly reactive immune response to all h5n1 influenza virus isolates is described. The optimized ha protein was developed through a series of ha protein alignments, and subsequent generation of consensus sequences, for clade 2 h5n1 influenza virus isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Ompa and asp14 in vaccine compositions and as diagnostic targets

Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Transgenic algae for delivering antigens to an animal

Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter.
The Ohio State University

Novel immunotherapy against several tumors, such as lung cancer, including nsclc

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin v to the subject.. .
The Board Of Trustees Of The Leland Stanford Junior University

Pegylated recombinant bacteriophage

The present invention provides a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant.

Specific akt3 inhibitor and uses thereof cross-reference to related applications

Methods of selectively inhibiting akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-n-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits akt3.
Augusta University Research Institute, Inc.

Psgl-1 modulators and uses thereof

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance.
Sanford-burnham Medical Research Institute

Antibody guided vaccines and methods of use for generation of rapid mature immune responses

Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both igg (in the circulation) and siga (mucosal secretory iga) is elicited.
The Texas A&m University System

Adjuvant for mucosal vaccine

An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (ha) subcomponents ha1 and ha2, and mutant subcomponent ha3 of botulinum toxin is provided..
Osaka University

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Microneedle compositions and methods of using same

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide.
Verndari, Inc.

Novel method and compositions

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants..
Glaxosmithkline Biologicals, S.a.

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Kif20a epitope peptides for th1 cells and vaccines containing the same

Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

The invention concerns a method of preparing a composition comprising stimulated immune system cells such as dendritic cells (dc) for use in inducing immune response of cytotoxic t lymphocytes against colorectal cancer. The dendritic cells are pulsed by contact with colorectal cancer stem cells (csc) or their fragments thereof.
Tessa Therapeutics Pte. Ltd.

Anti-psgl-1 antibodies

Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to p-selectin glycoprotein ligand-1. Also disclosed are methods of inducing death of an activated t-cell and of modulating a t cell-mediated immune response in a subject..
Abgenomics Cooperatief U.a.

Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein

The present invention relates to an isolated immunogenic peptide comprising a v2 loop fragment from hiv surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from hiv-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-hiv-1 antibodies which protect against hiv-1 infection.
New York University

Immunomodulatory compositions and methods for treating disease with modified host defense peptides

Compositions and methods are provided for modulating an immune response in a vertebrate subject. Compositions and methods can comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to activate the immune response in the vertebrate subject, wherein the modified host defense peptide is inverted in amino acid sequence from an amino terminus to a carboxy terminus or modified to one or more d-amino acids, or both modifications, when compared to a host defense peptide.
University Of Saskatchewan

Pharmaceutical combinations for immunotherapy

The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75ntr, which is expressed by plasmacytoid dendritic cells.
Technische Universitat Dresden

Lipidated immune response modifier compound compositions, formulations, and methods

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butyl) octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

New medical agents and uses thereof

The invention provides a novel compounds derived from cd154, but without the intracellular domain. Notably, the invention provides tmz-cd154 and a method to treat diseases in which the novel molecule tmz-cd154 is used.
Lokon Pharma Ab

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a pdgf polypeptide. Also disclosed is the use of these compositions to enhance wound healing..
Board Of Regents, The University Of Texas System

Immune mediated cancer cell destruction, systems and methods

Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.. .
Lazure Scientific, Inc.

Methods and materials for treating medical conditions

This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-interleukin 4, anti-interleukin 5, and/or anti-interleukin 13 antibodies to treat asthma in a mammal identified as having a th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided..
Mayo Foundation For Medical Education And Research

Methods for enhancing the efficacy of a tumor-directed immune response

As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an ox40 agonist and an indoleamine 2,3-dioxygenase (ido) inhibitor with the tumor antigen.. .
Augusta University Research Institute, Inc.

Synthetic glucopyranosyl lipid adjuvants

Or a pharmaceutically acceptable salt thereof, wherein l1, l2, l3, l4, l5, l6, l7, l8, l9, l10, y1, y2, y3, y4, r1, r2, r3, r4, r5, r6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided..

Vaccines with interleukin-17 as an adjuvant

Disclosed herein is a vaccine comprising an antigen and il-17. Also disclosed herein is a method for increasing an immune response in a subject.
Beijing Advaccine Biotechnology Co. Ltd

Vaccination with mrna-coded antigens

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Composite antigenic sequences and vaccines

The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection..
Longhorn Vaccines And Diagnostics, Llc

Cd40 ligand fusion protein vaccine

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein.
Microvax, Llc

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Induced activation in dendritic cells

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide..
Baylor College Of Medicine

Breast and ovarian cancer vaccines

The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids.
University Of Washington Through Its Center For Commercialization

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector..
The Texas A&m University System



Immune Response topics:
  • Immune Response
  • Antibodies
  • Polypeptide
  • Monoclonal
  • Monoclonal Antibody
  • Polymyxin B
  • Immunostimulator
  • Vaccination
  • Stimulator
  • Immunogenic
  • Nucleic Acid
  • Major Histocompatibility Complex
  • Histocompatibility
  • Vaccine Adjuvant
  • Compatibility


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Response for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Response with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.606

    file did exist - 13058

    1 - 1 - 253